All In Biotech

Drug Trial Radar · NCT05263583

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Dec 3, 2022

Primary completion

Feb 12, 2025

Study completion Feb 12, 2025

Sponsor

Lead sponsor
Cothera Bioscience, IncIndustry
Sponsor type
Industry
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma

Conditions

  • High-grade B-cell Lymphoma
  • Burkitt Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphatic Diseases
  • Lymphoma, High-Grade
  • C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
  • C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma
  • C-Myc Gene Rearrangement

Interventions

  • Sepantronium BromideDrug

    continuous intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability and recommended Phase 2 dose of sepantronium bromideTime frame: From time of signing informed consent through 30 days after the last dose of study drug, an average of 6 months

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Henan Cancer Hospital

    Henan, China

  • Shanghai East Hospital

    Pudong, China

  • Tianjin Cancer Hospital

    Tianjin, China

  • Tongji Hospital

    Wuhan, China

  • Dong-A University Hospital

    Busan, South Korea

  • Inje University Haeundae Paik hospital

    Busan, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Seoul St.Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.